Chemical Works of Gedeon Richter Plc (RGEDF)
43.76
+0.45
(+1.04%)
USD |
OTCM |
Aug 25, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 8.012B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 69.98% |
| Valuation | |
| PE Ratio | 12.16 |
| PE Ratio (Forward) | |
| PS Ratio | 2.826 |
| Price to Book Value | 1.835 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | 2.145 |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0141 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 56.37% |
Profile
| Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary. |
| URL | http://www.gedeonrichter.com |
| Investor Relations URL | N/A |
| HQ State/Province | Budapest |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 10, 2026 |
| Last Earnings Release | Aug. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 04, 2026 |
Profile
| Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary. |
| URL | http://www.gedeonrichter.com |
| Investor Relations URL | N/A |
| HQ State/Province | Budapest |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 10, 2026 |
| Last Earnings Release | Aug. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 04, 2026 |